Information needs of men on androgen deprivation therapy

BJU International

Volumn 109, Issue 10, 2012, Pages 1503-1509

  Soeyonggo, Tony ^a   Warde, Padraig ^b   Fleshner, Neil ^b   Timilshina, Narhari ^c   Alibhai, Shabbir M H ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Department of Radiation Oncology ^*  (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

androgen antagonists; attitudes; health knowledge; practice; prostatic neoplasms; questionnaires; salvage therapy

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RELAPSE; CONTROL PREFERENCES SCALE; CROSS-SECTIONAL STUDY; DECISIONAL REGRET SCALE; FATIGUE; GYNECOMASTIA; HEALTH SURVEY; HOT FLUSH; HUMAN; LANGUAGE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MONOTHERAPY; OVERALL SURVIVAL; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RATING SCALE; SATISFACTION WITH TREATMENT DECISION SCALE; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CROSS-SECTIONAL STUDIES; DECISION MAKING; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROGNOSIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84860345004     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10475.x     Document Type: Article

References (25)

1. Altekruse SF, Kosary CL, Krapcho M, et al,. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. Available at:, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Accessed 1 April 2011
2. Sharifi N, Gulley J, Dahut W,. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-44
3. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006; 98: 839-45
4. Shahinian V, Kuo YF, Freeman JL, Orihuela E, Goodwin JS,. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-24
5. Alibhai SMH, Gogov S, Allibhai Z,. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006; 60: 201-15
6. Gurwitz JW, Field TS, Harrold LR, et al,. Incidence and preventability of adverse drug events among older adults in the ambulatory setting. JAMA 2003; 289: 1107-16
7. Degner LF, Sloan JA,. Decision-making during serious illness: what role do patients really want to play. J Clin Epidemiol 1992; 45: 941-50
8. Holmes-Rovner M, Kroll J, Schmitt N, et al,. Patient satisfaction with health care decisions: the Satisfaction With Decision Scale. Med Decis Making 1996; 16: 58-64
9. Brehaut JC, O'Connor AM, Wood TJ, et al,. Validation of a decisional regret scale. Med Decis Making 2003; 23: 281-92
10. Alibhai SMH, Han RK, Naglie G,. Medication education of acutely hospitalized older patients. J Gen Intern Med 1999; 14: 610-6
11. Yogaparan T, Panju A, Minden M, Brandwein J, Mohamedali HZ, Alibhai SMH,. Information needs of adult patients 50 or older with newly diagnosed acute myeloid leukemia. Leuk Res 2009; 33: 1288-90
12. Tariman JD, Berry DL, Cochrane B, Doorenbos A, Schepp K,. Preferred and actual participation roles during health care decision making in persons with cancer: a systematic review. Ann Oncol 2010; 21: 1145-51
13. Davison BJ, Gleave ME, Goldenberg SL, Degner LF, Hoffart D, Berkowitz J,. Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nurs 2002; 25: 42-9
14. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P,. Prospective study of men's psychological and decisional-related adjustment after treatment for localized prostate cancer. Urology 2004; 63: 751-6
15. Hu JC, Kwan L, Saigal CS, Litwin MS,. Regret in men treated for localized prostate cancer. J Urol 2003; 169: 2279-83
16. Clark JA, Wray NP, Ashton CM,. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001; 19: 72-80
17. Alibhai SMH, Duong-Hua M, Sutradhar R, et al,. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27: 3452-8
18. Templeton H, Coates V,. Informational needs of men with prostate cancer on hormonal manipulation therapy. Patient Educ Couns 2003; 49: 243-56
19. Flaig TW, Glode LM,. Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother 2008; 9: 2829-41
20. Bolla M, Collette L, Blank L, et al,. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6
21. Messing EM, Manola J, Yao J, et al,. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-9
22. Lebret T, Coloby P, Descotes JL, Droupy S, Geraud M, Tombal B,. Educational tool-kit on diet and exercise: survey of prostate cancer patients about to receive androgen deprivation therapy. Urology 2010; 76: 1434-9
23. Sapir R, Catane R, Kaufman B, et al,. Cancer patient expectations of and communication with oncologists and oncology nurses: the experience of an integrated oncology and palliative care service. Support Care Cancer 2000; 8: 458-63
24. Bredart A, Boulec C, Dolbeault C,. Doctor-patient communication and satisfaction with care in oncology. Curr Opin Oncol 2005; 17: 351-4
25. Cegala DJ, Bahnson RR, Clinton SK, et al,. Information seeking and satisfaction with physician-patient communication among prostate cancer survivors. Health Commun 2008; 23: 62-9